Prime Medicine, Inc.
$3.89
▼
-2.06%
2026-04-21 08:57:00
primemedicine.com
NGM: PRME
Explore Prime Medicine, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$687.9 M
Current Price
$3.89
52W High / Low
$6.94 / $1.11
Stock P/E
—
Book Value
$0.68
Dividend Yield
—
ROCE
-68.25%
ROE
-1.47%
Face Value
—
EPS
$-1.35
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
146
Beta
2.67
Debt / Equity
96.33
Current Ratio
4.84
Quick Ratio
4.84
Forward P/E
-4.31
Price / Sales
133.7
Enterprise Value
$546.13 M
EV / EBITDA
-2.72
EV / Revenue
117.9
Rating
Buy
Target Price
$6.92
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Sagimet Biosciences Inc. | $6.44 | — | $206.19 M | — | -51.08% | -38.2% | $11.41 / $2.02 | $3.42 |
| 2. | Invivyd, Inc. | $1.68 | — | $492.08 M | — | -22.89% | -33.97% | $3.07 / $0.46 | $0.86 |
| 3. | Kairos Pharma, Ltd. | $0.63 | — | $13.1 M | — | -87.87% | -97.99% | $2.11 / $0.4 | $0.37 |
| 4. | Beam Therapeutics Inc. | $31.19 | — | $3.2 B | — | -27.72% | -8.11% | $36.44 / $15.35 | $12.48 |
| 5. | Acumen Pharmaceuticals, Inc. | $2.84 | — | $203.64 M | — | -133.4% | -96.2% | $3.6 / $0.85 | $1.16 |
| 6. | Lexeo Therapeutics, Inc. | $6.53 | — | $511.94 M | — | -85.23% | -55% | $10.99 / $2.19 | $3.38 |
| 7. | Elicio Therapeutics, Inc. | $12.2 | — | $224.43 M | — | -210.11% | 817.92% | $14.93 / $4.7 | $0.09 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.84 M | 1.23 M | 1.11 M | 1.45 M | 2.18 M | — |
| Operating Profit | -48.61 M | -53.97 M | -53.38 M | -52.39 M | -44.22 M | — |
| Net Profit | -46.08 M | -50.58 M | -52.59 M | -51.89 M | -42.28 M | — |
| EPS in Rs | -0.26 | -0.28 | -0.29 | -0.29 | -0.23 | -0.44 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 4.63 M | 2.98 M | 0 M | 0 M |
| Operating Profit | -208.35 M | -202.47 M | -191.29 M | -116.54 M |
| Net Profit | -201.14 M | -195.88 M | -198.13 M | -121.82 M |
| EPS in Rs | -1.11 | -1.08 | -1.1 | -0.67 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 342.73 M | 297.51 M | 193.85 M | 360.31 M |
| Total Liabilities | 221.87 M | 144.36 M | 60.78 M | 44.04 M |
| Equity | 120.87 M | 153.15 M | 133.07 M | 316.27 M |
| Current Assets | 181.29 M | 211.89 M | 142.98 M | 296.62 M |
| Current Liabilities | 37.45 M | 37.96 M | 56.42 M | 26.71 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -162.56 M | -122.86 M | -165.41 M | -131.83 M |
| Investing CF | -108.76 M | 68.46 M | 18.71 M | -47.1 M |
| Financing CF | 151.51 M | 195.88 M | 0.66 M | 181.49 M |
| Free CF | -167.09 M | -130.16 M | -174.14 M | -147.92 M |
| Capex | -4.53 M | -7.29 M | -8.72 M | -16.09 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 1.14% | -62.64% | — | — |
| Profit Margin % | -6566.61% | — | — | — |
| Operating Margin % | -6787.36% | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -6581.93% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.